Skip to main content

United Therapeutics Corp. (NASDAQ: UTHR) reworks deal with Eli Lilly & Co. (NYSE: LLY) ahead of patent expiration – Washington Business Journal

By May 22, 2017News
united-therapeutics-logo

united-therapeutics-logo

Silver Spring drugmaker United Therapeutics Corp. extended an exclusive license with drug giant Eli Lilly & Co. to cover its pulmonary hypertension drug Adcirca, which will lose part of its patent protection later this year.

{iframe}http://www.bizjournals.com/washington/news/2017/05/19/united-therapeutics-reworks-deal-ahead-of-a-key.html?ana=e_me_set1&s=newsletter&ed=2017-05-19&u=tgsFWC4bmAJifJaD7aSENg0a82e31f&t=1495467311&j=78206601{/iframe}

Leave a Reply

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.